ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,881 to 3,900 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Serious Vaccine-Related Adverse Experiences0 of 1,415

1 of 334

-0.3 points

-1.7 to 0.1

1,749NCT00326183

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Systemic Adverse Experiences782 of 1,415

197 of 334

-3.7 points

-9.5 to 2.2

1,749NCT00326183

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

CT Coronary Angiogram vs Standard Care: Invasive Coronary Angiography474 of 877

530 of 871

-6.8 points

-11.4 to -2.2

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Subsequent Non-fatal MI (Type 1 or 4b)35 of 877

38 of 871

-0.4 points

-2.3 to 1.5

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Coronary Revascularisation300 of 877

288 of 871

1.1 points

-3.3 to 5.6

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Coronary Heart Disease Death11 of 877

6 of 871

0.6 points

-0.4 to 1.6

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Discharged on Preventative Treatment or Alteration in Dosage of Preventative Treatment During Index Hospitalisation554 of 877

539 of 871

1.3 points

-3.2 to 5.8

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Cardiovascular Disease Death or Subsequent Non-fatal MI48 of 877

46 of 871

0.2 points

-2.0 to 2.3

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Coronary Heart Disease Death or Subsequent Non-fatal MI47 of 877

45 of 871

0.2 points

-1.9 to 2.3

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Representation or Rehospitalisation With Suspected ACS/ Recurrent Chest Pain After Index Hospitalisation138 of 877

130 of 871

0.8 points

-2.6 to 4.2

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event.51 of 877

53 of 871

-0.3 points

-2.5 to 2.0

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Cardiovascular Death12 of 877

8 of 871

0.4 points

-0.6 to 1.6

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Percutaneous Coronary Intervention260 of 877

240 of 871

2.1 points

-2.1 to 6.3

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Subsequent Non-fatal MI39 of 877

40 of 871

-0.1 points

-2.1 to 1.8

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Number of Patients Prescribed ACS Therapies During Index Hospitalisation595 of 877

580 of 871

1.3 points

-3.1 to 5.6

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Coronary Artery Bypass Graft52 of 877

55 of 871

-0.4 points

-2.7 to 1.9

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Coronary Heart Disease (CHD) Death or Subsequent Non-fatal MI (Type 1 or 4b)43 of 877

43 of 871

-0.0 points

-2.1 to 2.0

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: All-cause Death19 of 877

17 of 871

0.2 points

-1.2 to 1.6

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: Non-cardiovascular Death7 of 877

9 of 871

-0.2 points

-1.2 to 0.7

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

CT Coronary Angiogram vs Standard Care: deaths from any cause19 of 877

17 of 871

0.2 points

-1.2 to 1.6

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=195"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=195

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00326183-bdc1d47d",
        "title": "Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Serious Vaccine-Related Adverse Experiences",
        "summary": "0 of 1415 against 1 of 334; risk difference -0.3 points, 95% interval -1.7 to 0.1; NCT00326183, Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)",
        "record": "/library/comparisons/NCT00326183-bdc1d47d",
        "nct_id": "NCT00326183",
        "kind": "outcome",
        "participants": 1749,
        "risk_difference": {
          "value": -0.0029940119760479044,
          "lower": -0.016761820499682663,
          "upper": 0.0006676885955971788
        },
        "group_1": "0 of 1,415",
        "group_2": "1 of 334",
        "difference": "-0.3 points",
        "interval": "-1.7 to 0.1",
        "trial_title": "Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)"
      },
      {
        "id": "NCT00326183-be2c2a60",
        "title": "Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Systemic Adverse Experiences",
        "summary": "782 of 1415 against 197 of 334; risk difference -3.7 points, 95% interval -9.5 to 2.2; NCT00326183, Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)",
        "record": "/library/comparisons/NCT00326183-be2c2a60",
        "nct_id": "NCT00326183",
        "kind": "outcome",
        "participants": 1749,
        "risk_difference": {
          "value": -0.037170182602991986,
          "lower": -0.09481238545603868,
          "upper": 0.022177770475446106
        },
        "group_1": "782 of 1,415",
        "group_2": "197 of 334",
        "difference": "-3.7 points",
        "interval": "-9.5 to 2.2",
        "trial_title": "Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=196",
  "request_id": "8cuWizSVoow1I5JZ"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?